About Irinotecan
            
            Class: | Antineoplastic agent, Topoisomerase I inhibitor  
Use: | Treatment of metastatic colorectal cancer, often in combination with other chemotherapy agents; also used in small cell lung cancer.  
Adult dose: | Initial dose is typically 125 mg/m² administered as an intravenous infusion over 90 minutes every 21 days, adjusted based on tolerance and side effects.  
Pediatric dose: | Safety and efficacy not established; use in pediatric patients should be based on clinical judgment and specific
         
        
            
                
                
                    
                        Drug Class
                    
                    Antineoplastic agent, Topoisomerase I inhibitor
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of metastatic colorectal cancer, often in combination with other chemotherapy agents; also used in small cell lung cancer.
                 
                
                
                    
                        Storage Requirements
                    
                    Store at 20°C to 25°C (68°F to 77°F); protect from light and moisture; do not freeze.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: seacross pharmaceuticals, United Kingdom
                    
                    
                    Package Size
                    1s
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 324.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose is typically 125 mg/m² administered as an intravenous infusion over 90 minutes every 21 days, adjusted based on tolerance and side effects.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established; use in pediatric patients should be based on clinical judgment and specific protocols.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include diarrhea, nausea, vomiting, abdominal pain, fatigue, neutropenia, and alopecia.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to irinotecan or any component of the formulation; severe bone marrow suppression; diarrhea; pregnancy and lactation (unless benefits outweigh risks).
         
        
        
            
                Important Warnings
            
            Risk of severe diarrhea, which may be life-threatening; monitor for signs of dehydration; may cause myelosuppression; caution in patients with hepatic impairment; potential for secondary malignancies.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.